Document is current

Article History

Received: 1 July 2021

Accepted: 18 October 2021

First Online: 1 November 2021

Competing interests

: S.C. reports advisory role and/or travel compensation: Bristol‐Myers Squibb Recipient F, Hoffmann La Roche AG, Pfizer, Boehringer Ingelheim, MSD Oncology, Amphera. P.I. reports advisory role and/or travel compensation: Bristol‐Myers Squibb Recipient, F. Hoffmann, La Roche AG, Merck Sharp & Dohme, Boehringer Ingelheim, MSD Oncology, Rovi, Kyowa Kirin, Grunenthal Pharma S.A., Pfizer, Medscape, Kern Pharma. A.C. reports advisory role and/or travel compensation: Bristol‐Myers Squibb Recipient, F. Hoffmann La Roche AG, Pfizer, Boehringer Ingelheim, MSD Oncology, Kyowa Kirin, Celgene, Leo Pharma, Medscape, Kern Pharma. N.P. reports advisory role and/or travel compensation: MSD Oncology, Merck Sharp and Dohme, Bristol‐Myers Squibb Recipient, F. Hoffmann La Roche AG, Pfizer, Boehringer Ingelheim, Grunenthal Pharma, S.A, Kern Pharma. A.N. reports advisory role, speaker’s bureau or travel compensation: Bristol‐Myers Squibb, F. Hoffmann La Roche AG, Pfizer, Boehringer Ingelheim, Oryzon Genomics, Oryzon Genomics, Astra Zeneca. A.M.M. provided consultation, attended advisory boards and/or speaker's bureau for the following organizations: BMS, Roche, MSD, Pfizer, Boehringer Ingelheim, AstraZeneca. C.C. and J.F. had been partially supported by Grant for Oncology EMD Serono research funding to EF. R.D. advisory role at Roche, Boehringer Ingelheim, has received a speaker’s fee from Roche, Ipsen, Amgen, Servier, Sanofi, Merck Sharp & Dohme, research grant from Merck and Pierre Fabre. E.F. reports the following conflicts of interest: advisory role or speaker’s bureau: AbbVie, AstraZeneca, BerGenBio, Beigene, Bayer, Blueprint medicines, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, Eli Lilly, Glaxo smith kline, Guardant Health, Janssen, Medscape, Merck KGaA, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, priME Oncology, Peptomyc, Peervoice, Puma, Regeneron, Sanofi, Syneos Health, Springer, Roche, Samsung, Takeda, Touchtime. Board: Grifols, independent member. Research funding: Fundación Merck Salud, Grant for Oncology Innovation EMD Serono. C.C. and J.F. had been partially supported by Grant for Oncology EMD Serono research funding to EF. All remaining authors have declared no conflicts of interest.